Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol

By afschroeder • August 29, 2025

Holzgreve A, Delker A, Ells Z, Brosch-Lenz J, Unterrainer LM, Nikitas J, Zhu S, Contreras MM, Alam H, Nabong RM, Lira S, Vasilyev A, Chen L, Grogan T, Elashoff D, Meyer CA, Dahlbom M, Czernin J, Calais J. Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of ¹⁷⁷Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. J Nucl Med. 2025 Aug 28:jnumed.125.269495. doi: 10.2967/jnumed.125.269495. Epub ahead of print. PMID: 40876952.

Tags: [177Lu]Lu-PSMA-617, DOM STAT, General Internal Medicine, mCRPC, metastatic castration-resistant prostate cancer, Primary Care, prostate-specific membrane antigen, PSMA, Publications, radiopharmaceutical therapy, RPT, SPECT/CT, therapy response assessment, treatment holidays

Validating ICD code case definitions for condition case ascertainment in multimorbidity measurement: a retrospective chart review

Kang AJ, Tseng CH, Wei MY. Validating ICD code case definitions for condition case ascertainment in multimorbidity measurement: a retrospective chart review. J Gerontol A[...]

Defining Diagnostic Excellence and Missed Diagnostic Opportunity for the Emergency Department Setting

Berdahl CT, Schiff GD, Venkatesh AK, Seferian EG, Torbati SS, Ptacek MP, Carrascoza-Bolanos J, Qureshi N, Nuckols TK; Multidisciplinary ED Diagnostic Excellence Panel. Defining Diagnostic[...]

Development and mixed-methods evaluation of the Prehabilitation for Facial Feminization Surgery (PREFACE) Program

Hall AE, Nguyen NH, Argame AA, Patel AK, Hargrove RJ, Khetpal S, Cascavita CT, Nguyen-Buckley CT, Rada RC, Tseng CH, Hidalgo MA, Lee JC. Development[...]